Mexico City, August 10, 2025 – The Mexican government of President Claudia Sheinbaum announced this week an injection of 12 billion MX Pesos ($643.4 million) from four major pharmaceutical companies with both national and international links, aimed at investments in core industries and expanding innovation in the research, manufacturing, and technology spaces of Mexican bioscience sectors.
At a Thursday press conference, David Kershenobich, Mexico’s Ministry of Health, applauded the initiative as a demonstration of growing investor confidence in Sheinbaum’s recent strides in the healthcare sector.
President Sheinbaum has made healthcare part of her core tenets of the administration, specifically focusing on the industrialization and innovation of science and medicine.
Sheibaum has geared her administration to focus on the viability of effective and affordable healthcare, and part of this requires a complete modernization of the current system. An ambitious effort, but one that will also rely heavily on domestic production and in-house innovations in research & development, and technology.
Sheibaum has stressed that Mexico has become too dependent on the imports of foreign medicine and pharmaceutical products (currently 65%), while pushing to boost domestic production for self-sufficiency as part of national security aims to insulate the nation’s sick and infirm in case of another global pandemic like COVID-19 in 2020.
“These investments will strengthen the country’s health sovereignty, boost local production of essential medicines, modernize infrastructure, and promote exports,” says Kershenobich.
According to projections produced by the Mexican government, the investments have the capacity to generate roughly 3,000 new jobs in Mexico and about 20,000 jobs indirectly in other regions, according to Mexico Business News.
As part of the investments, German private medical firm Boehringer Ingelheim “will invest MX$3.5 billion (US$187.5 million) to expand its manufacturing site in Xochimilco, Mexico City, making it the company’s largest global plant for tablet production.”
Ingelheim, a stalwart in the German medical space, has managed to retain its private ownership since the mid-1860s, plans on manufacturing 5 billion tablets at the Xochimilco site annually for conditions such as hypertension and diabetes, with exports planned to over 40 countries.
German multinational giant, Bayer, will invest MX$3 billion (US$160.8 million) over the next five years to expand its operations in Mexico, expanding its ingredient plant and agri-technology operations in Veracruz and Tlaxcala.
The third company, British giant AstraZeneca will allocate over MX$2 billion (US$107.2 million) across three initiatives: research; digital upgrades; and production modernization in the State of Mexico.
Lastly, AstraZeneca’s firm Carnot Laboratorios “plans to invest MX$3.5 billion (US$187.5 million) in a new pharmaceutical and biotech plant in Hidalgo, which focuses on exports to over 30 countries”, according to Mexico Business News, creating 600 direct new jobs and approximately 5,000 indirectly throughout the region.
